← Leaderboards
Reto Andreas Gadient
Camino Pharma, Llc
$1,575,597
Attributed
$2,888,160
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.9K · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,888,160 · 2
By mechanism
U43$1,968,844 · 1
R43$919,316 · 1
Top collaborators
- Robert Warren Gould2 shared
- Douglas J Sheffler2 shared
Others in their field
Other Emerging Leaders on “Prefrontal Cortex”
- Hemali Phatnani · New York University School Of Medicine$13,225,131
- Fabio Ferrarelli · University Of Pittsburgh At Pittsburgh$8,472,410
- Amy F Arnsten · Yale University$8,074,219
- Zafiris J. Daskalakis · Centre For Addiction And Mental Health$6,974,312
- Fritzie Isip Arce-McShane · University Of Chicago$6,731,855
- Erik C.b. Johnson · Emory University$6,587,766
Research focus
Prefrontal CortexPharmaceutical PreparationsMetabotropic Glutamate ReceptorsPreclinical DevelopmentSmall MoleculePlasmaGlutamatesMetabotropic Glutamate Receptor 2Novel Drug ClassPlayRodentRodent ModelAffectRattusAcuteDoseIn VivoMedicalAdultNeuronsAlcoholsAlcohol RelapseAdverse EventAnimal Experiments
Grant awards (4)
Preclinical validation of mGlu2 PAMs in alcohol use disorder$994,906
U43 · FY2024 · AA · contact PI
Preclinical validation of mGlu2 PAMs in alcohol use disorder$973,938
U43 · FY2023 · AA · contact PI
Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptors 2 & 3 (mGlu2/3) for the Treatment of Depression$449,453
R43 · FY2021 · MH · contact PI
Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptors 2 & 3 (mGlu2/3) for the Treatment of Depression$469,863
R43 · FY2020 · MH · contact PI